Page last updated: 2024-10-30

lansoprazole and Autoimmune Diabetes

lansoprazole has been researched along with Autoimmune Diabetes in 3 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Research Excerpts

Excerpt	Relevance	Reference
"Children aged 6-12 years with type 1 diabetes were allocated to receive cholecalciferol and lansoprazole (Group 1) or no treatment (Group 2)."	1.72	Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study. ( Attri, SV; Dayal, D; Gupta, VK; Reddy, R; Sachdeva, N, 2022)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Reddy, R	3
Dayal, D	3
Sachdeva, N	3
Attri, SV	3
Gupta, VK	3
Levetan, C	1
Pozzilli, P	1
Jovanovic, L	1
Schatz, D	1
Griffin, KJ	1
Thompson, PA	1
Gottschalk, M	1
Kyllo, JH	1
Rabinovitch, A	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.[NCT01762644]	Phase 3	0 participants (Actual)	Interventional	2015-08-31	Withdrawn (stopped due to This study was withdrawn prior to enrollment.)
Combination Therapy With Sitagliptin (DPP 4 Inhibitor) and Lansoprazole (PPI) Inhibitor) to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes[NCT01155284]	Phase 2	70 participants (Actual)	Interventional	2010-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

2 Hour C-peptide AUC in Response to MMTT

Blood samples for C-peptide were collected at baseline (pre-meal) and 15, 30, 60, 90 and 120 minutes post-meal. (NCT01155284)
Timeframe: Month 12

Intervention	pmol/L (Median)
Sitagliptin and Lansoprazole	358
Placebo	495

2 Hour C-peptide AUC in Response to MMTT

Blood samples for C-peptide were collected at baseline (pre-meal) and 15, 30, 60, 90, and 120 minutes post-meal. (NCT01155284)
Timeframe: Month 6

Intervention	pmol/L (Median)
Sitagliptin and Lansoprazole	485
Placebo	675

Trials

1 trial available for lansoprazole and Autoimmune Diabetes

Article	Year
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9 Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin	2014
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9 Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin	2014
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9 Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin	2014
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9 Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin	2014

Other Studies

2 other studies available for lansoprazole and Autoimmune Diabetes

Article	Year
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study. Einstein (Sao Paulo, Brazil), 2022, Volume: 20 Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu	2022
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study. Einstein (Sao Paulo, Brazil), 2022, Volume: 20 Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu	2022
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study. Einstein (Sao Paulo, Brazil), 2022, Volume: 20 Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu	2022
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study. Einstein (Sao Paulo, Brazil), 2022, Volume: 20 Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu	2022
Proposal for generating new beta cells in a muted immune environment for type 1 diabetes. Diabetes/metabolism research and reviews, 2013, Volume: 29, Issue:8 Topics: Animals; Cyclosporine; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Ga	2013